Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. (2023)
Attributed to:
Respiratory infections
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(22)02597-1
PubMed Identifier: 36566761
Publication URI: http://europepmc.org/abstract/MED/36566761
Type: Journal Article/Review
Volume: 401
Parent Publication: Lancet (London, England)
Issue: 10373
ISSN: 0140-6736